ArticleFrontiers in genetics2025
Characterization of lactylation modification subtypes and the promoting role of CCL20 in hepatocellular carcinoma progression.
Article in Frontiers in genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Molecular Signaling Pathways, Regulatory and Coactivator Networks, and Emerging Mechanisms in Hepatocellular Carcinoma.Biomedicines · 2026Review
- Lactylation in tissue fibrosis: epigenetic mechanisms, metabolic crosstalk, and therapeutic opportunities.Journal of translational medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatocellular carcinoma (HCC) is a highly aggressive and deadly malignancy. Early identification of prognostic risk factors is crucial for guiding clinical management and improving patient outcomes. Lactylation modification plays a pivotal role in tumorigenesis, yet the regulatory mechanisms and prognostic significance of lactylation-related genes in HCC remain insufficiently understood. Methods: This study screened for prognostically significant lactylation modification-related genes based on their expression levels, integrated with DFS, PFS, and OS data. HCC patients were stratified into three distinct lactylation modification subtypes (C1, C2, C3) using the NMF algorithm. Differentially expressed genes across the three subtypes were identified through an intersection analysis. A lactylation modification-related prognostic model was subsequently constructed using LASSO-Cox and multivariate Cox regression analyses. The CIBERSORT algorithm was utilized to analyze immune cell infiltration. Functional validation of the lactylation-related gene CCL20 in HCC was conducted through Results: We identified three distinct lactylation modification patterns, with higher lactylation modification levels correlating with worse prognosis in HCC. A six-gene lactylation modification-based prognostic model (LRPS), including FAM83D, ENO1, PFN2, LCAT, PTGR1, and CCL20, was constructed and validated. Overall survival was markedly reduced in the high LRPS group relative to the low LRPS group. The high LRPS group also showed a significantly higher frequency of TP53 mutations. Correlation analysis of immune cell infiltration revealed a significant association between LRPS and the infiltration abundance of M0 macrophages, Tregs, and neutrophils, suggesting that lactylation modification may influence the tumor immune microenvironment. Overexpression of CCL20 in HCC cells significantly enhanced their proliferative and migratory capacities, indicating a key role for CCL20 in HCC progression. Conclusion: This study established a lactylation modification-based prognostic model that accurately forecasts outcomes in HCC patients. This risk score showed a significant correlation with glucose metabolism and reflected immune cell infiltration patterns. The core model gene, CCL20, promotes HCC cell proliferation and migration, supporting its potential as a valuable prognostic biomarker and a therapeutic target for HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.